Recent developments include a reported drop in Q3 profit in October 2025, insider buying activity in 2025, trading halts and resumptions in late 2024, and strategic plans to explore alternatives and a potential spin-off of the Celle subsidiary.

• Cryo-Cell International reported a drop in Q3 profit in October 2025 [N1].
• Insider buying activity involving CCEL was reported in September and August 2025 [N2][N3].
• An earnings preview in April 2025 highlighted recent insider trading and hedge fund activity [N4].
• Trading of CRYO-CELL International was halted and then resumed in October 2024 due to volatility [N6][N5].
• In March 2024, Cryo-Cell announced plans to explore strategic alternatives and a potential spin-off of its Celle subsidiary [N8].

Cryo-Cell benefits from its pioneering position and extensive specimen inventory, which may support continued demand for cord blood and tissue storage services. Its accredited, compliant facilities and proprietary processing technology differentiate it in the market. The company’s expansion into third-party cold storage services through ExtraVault leverages existing infrastructure and expertise. The public cord blood banking segment and international licensing agreements provide additional revenue streams. Insider buying activity reported in 2025 may indicate confidence in the company’s prospects. The company’s marketing efforts targeting expectant parents and prenatal care providers aim to increase awareness and enrollment, potentially expanding its customer base [N2,N3,N4].

The termination of the Duke License Agreement and the resulting pause in the Cryo-Cell Institute for Cellular Therapies and Celle subsidiary spin-off create uncertainty around the company’s ability to diversify into infusion clinics and biopharmaceutical manufacturing. The company recorded a full impairment charge of $13.1 million related to this agreement, reflecting the setback. Liquidity ratios as of February 28, 2026, indicate constraints with a current ratio of 0.62 and cash ratio of 0.16. Revenue has declined modestly due to fewer new domestic cord blood specimens processed, and legal expenses related to the Duke dispute have increased. Competition in the cord blood banking market remains intense, and market penetration is limited by cost perceptions and awareness challenges. The company’s financial performance and ability to secure additional financing may be affected by these factors [S1,S2,N1].

Cryo-Cell's competitive advantages include its status as the world's first private cord blood bank with over 250,000 specimens stored globally, accredited and compliant facilities with cGMP/cGTP standards, and a state-of-the-art processing laboratory. The company utilizes proprietary processing technology that maximizes healthy stem cell recovery and offers unique features such as a five-compartment cord blood freezer bag for multiple uses. Its secure, monitored storage environment and a payment warranty for engraftment failure provide additional client assurance. The company’s established client base, combined with its marketing and educational outreach, supports market penetration. Its public cord blood inventory and listing on the NMDP registry further enhance its position. However, the termination of the Duke License Agreement and the pause of related business expansions represent challenges to diversification and growth.

• Duke License Agreement Termination: The termination of the Duke License Agreement as of May 17, 2025, has paused the company’s expansion into infusion clinics and biopharmaceutical manufacturing, and the Cryo-Cell Institute for Cellular Therapies remains unopened. The outcome of related arbitration and disputes may materially affect future operations and investments [S1,S5].
• Liquidity Constraints: As of February 28, 2026, the company’s current ratio is 0.62 and cash ratio is 0.16, indicating potential liquidity challenges. The company may need to reduce or defer expenditures or seek additional financing, which may not be available on favorable terms [S2,S15,S16].
• Market Penetration and Competition: The cord blood stem cell preservation market has relatively low penetration compared to total births, partly due to cost perceptions and lack of awareness. Increasing competition from public and private banks may pressure revenues and margins [S1,S4].
• Legal and Regulatory Risks: The company faces legal expenses related to the Duke dispute and potential risks from intellectual property claims, regulatory compliance, and operational risks in storage facilities. Any material failure or compromise could adversely affect reputation and financial condition [S1,S2,S3].
• Dependence on Technological and Medical Advances: The company’s business depends on evolving medical technology and acceptance of stem cell therapies. Technological breakthroughs that render current preservation methods obsolete could adversely impact the business [S1,S2].

• Cryo-Cell International, Inc. is a Delaware corporation incorporated in 1989 and was the world's first private cord blood bank to separate and store stem cells in 1992 [S1].
• The company operates three reportable segments: (1) cellular processing and cryogenic storage for family use focusing on umbilical cord blood and tissue stem cells, (2) manufacture of the PrepaCyte® CB Processing System used to process umbilical cord blood stem cells, and (3) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use [S1].
• Cryo-Cell and its global affiliates currently store over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborns and possibly their families [S1].
• The company’s U.S. operations, including processing and storage, are based in Oldsmar, Florida, with specimens primarily stored in cryogenic storage units at a facility in Durham, North Carolina [S1].
• Cryo-Cell offers cord blood and cord tissue storage services, charging fees for processing, testing, and first-year storage, with annual fees thereafter unless prepaid for 18 years or lifetime [S1,S4].
• The company’s facilities are cGMP- and cGTP-compliant, with AABB and FACT accreditation, and include a state-of-the-art laboratory and secure cryogenic storage designed for safety and redundancy [S1,S4].
• Cryo-Cell introduced a cord tissue service in 2011, storing a section of umbilical cord tissue rich in mesenchymal stromal cells (MSCs) with potential regenerative properties [S1].
• In 2018, Cryo-Cell acquired assets of Cord:Use Cord Blood Bank, expanding its public cord blood banking inventory, which is sold through the National Marrow Donor Program (NMDP) [S1].
• The company purchased a 56,000 square-foot facility in Durham, NC, to support anticipated operations related to a now-terminated Duke University License Agreement and to offer third-party cold storage services branded as ExtraVault [S1].
• Cryo-Cell’s business model includes marketing to expectant parents and prenatal care providers to increase awareness and enrollment in stem cell preservation programs, using online advertising and a national team of field educators [S1,S4,S20].
• The company faces competition from other private and public cord blood banks, with market penetration still relatively low compared to total births in the U.S. due to cost perceptions and lack of awareness [S1,S4].
• Cryo-Cell entered into a Patent and Technology License Agreement with Duke University in 2021 to develop expanded business units including infusion clinics and biopharmaceutical manufacturing, but Duke terminated the agreement effective May 17, 2025, and the company paused related investments and the planned Cryo-Cell Institute for Cellular Therapies [S1,S4,S5].
• The company recorded a full impairment charge of $13.1 million related to the Duke License Agreement assets in fiscal 2023 [S5].
• Financial snapshot as of 2026-02-28 from the latest 10-Q: cash and equivalents $249,672; short-term investments $2,650,386; current assets $11,076,980; current liabilities $17,763,567; current ratio 0.62; cash ratio 0.16; net income $47,108; basic and diluted EPS $0.01 [S2].
• Revenue was $7.68 million for the three months ended February 28, 2026, down 4% from prior year, with processing and storage fees declining due to fewer new domestic cord blood specimens processed, offset partially by recurring annual storage fees [S2].
• Cost of sales decreased 17% for the three months ended February 28, 2026 compared to prior year, reflecting process enhancements and lower public bank costs [S2].
• Selling, general and administrative expenses increased, including legal fees related to the Duke dispute [S2].
• The company has a revolving credit facility and term loan with Susser Bank, with interest rate swap agreements to manage variable rate debt exposure [S15,S18].
• Cryo-Cell has license agreements to market its cord blood stem cell programs in several Central American countries [S20].
• The company’s public cord blood units are listed on the NMDP registry, which connects to major international registries and serves as a single point of access for transplant centers [S19,S20].
• Recent news highlights include a Q3 profit drop reported in October 2025, insider buying activity reported in 2025, trading halts and resumptions in late 2024, and plans to explore strategic alternatives and a spin-off of Celle subsidiary announced in March 2024 [N1,N2,N3,N4,N5,N6,N8].